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doi:10.1016/j.ejvs.2011.07.010Abstract Objectives: The aim of the study is to study contemporary presentation patterns
and clinical results in patients undergoing aortofemoral bypass (AFB) surgery.
Design: This was a retrospective comparative study.
Material and methods: During a 14-year period, 269 consecutive patients (mean age 65 years)
underwent AFB. Indications included occlusive disease with severe intermittent claudication
(IC) (nZ 86), critical limb ischaemia (CLI, nZ 97) and aneurysmo-occlusive disease (nZ 86).
Results: From 2000e07 on, AFB was performed more frequently for occlusive disease with CLI
than for other indications (48% vs. 31% before 2000, PZ 0.009) and also in women (51% vs. 32%
before 2000, P Z 0.003), compared to the period before 2000. Thirty-day mortality was
reduced during 2000e2007 to 2.4%, compared with 4.3% during 1993e1999, although this
difference was not statistically significant (P Z 0.73). Morbidity did not change substantially
over the study period. Predictors of 30-day mortality included indication (CLI Z 4.1% vs.
c l aud icat ion Z 1.2% (P Z 0 .37 ) ) and chron ic k idney d i sease (CKD, se rum
creatinine > 1.5 mg dl1) (11.1% vs. 2.9% in normal renal function, PZ 0.07), the latter being
the single predictor on multivariate analysis (hazard risk 4.2, PZ 0.047). Overall 5 and 10-year
assisted primary and secondary patency was 95% and 88%, and 99% and 95%, respectively.
Survival at 5 and 10 years was 69% and 48%, respectively. Patient age (hazard risk 1.05,
P < 0.001), CKD (hazard risk 1.79, PZ 0.018) and diabetes (hazard risk 1.56, PZ 0.022) were
independent predictors of worse long-term survival. Long-term outcome did not change over
the course of the study.
Conclusions: In the contemporary era, AFB is more likely to be performed for CLI and in women
than in the past. Despite these changes, perioperative mortality and morbidity remain low and
long-term outcome excellent.
ª 2011 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.3 916 3155; fax: þ1 313 916 3023.
(A.D. Shepard).
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AF2 Bypass Grafting in the Era of Endovascular Procedures 659Aortofemoral bypass (AFB) grafting is considered the gold-
standard procedure for treating aorto-iliac occlusive
disease (AIOD) because of excellent and durable results.1e4
In recent years, minimally invasive endovascular tech-
niques have been increasingly employed for AIOD.5e7
Endovascular techniques are usually applied to Trans-
Atlantic Inter-Society Consensus (TASC II) A and B
disease,8 while AFB grafting is reserved for more advanced
AIOD, a disease pattern often seen in the elderly and in
patients with multiple co-morbidities, who frequently
experience a more complicated postoperative course. As
a result of the widespread use of endovascular treatment
for less severe cases, the presentation pattern and outcome
of patients undergoing AFB grafting may have changed. An
increasing complexity of open aortofemoral reconstruction
done in the era of routine endovascular interventions has
been recognised.9e11 In one recent series, AFB grafting was
performed as a secondary or even tertiary procedure (after
failure of previous endovascular and/or open procedure) in
almost half of the patients and complex procedures were
required in over a third of these cases.11 As only short-term
results were reported, the long-term outcome of AFB
grafting in this setting remains unknown.
The aim of the present study was to investigate
contemporary presentation patterns, short- and long-term
clinical results and predictors of short-term and long-term
mortality in patients undergoing AFB surgery in the endo-
vascular era. The implications of changing patterns of
presentation and outcome in recent years are important, as
this information could be useful in the process of operative
decision making, patient counselling and informed consent.Material and Methods
During the period of January 1993 through June 2007, 269
consecutive patients (167 men, mean age 65 years)
underwent AFB in our institution. Indications included AIOD
with severe intermittent claudication (IC) (n Z 86),
ischaemic rest pain (n Z 67) or tissue loss (n Z 30) and
aneurysmo-occlusive disease (n Z 86), the latter being
defined as the combination of an infrarenal abdominal
aorto-iliac aneurysm and iliac atherosclerosis (most
frequently involving the external iliac arteries), not
permitting durable aortobiiliac prosthetic grafting. Severe
IC was defined as the presence of disabling symptoms or
maximum walking distance of one block. In 20 patients with
aneurysmo-occlusive disease (23%), the primary indication
for AFB was severe IC or critical limb ischaemia (CLI), while
four additional patients (4.6%) presented with
atheroembolism.
Patients included in the present study were either
referred to the outpatient clinic by their primary care
physicians or presented to our emergency room with CLI.
Following appropriate preoperative evaluation, the
responsible attending surgeon made the decision to
proceed with AFB surgery (as opposed to angioplasty and/or
stenting, non-operative management or primary amputa-
tion). Patient information was retrieved from a prospective
database and hospital electronic records and was supple-
mented by the Internet-based social security death index.
Patients were divided in two groups: 1993e1999 (before2000) and 2000e2007 (after 2000). This break was due to
the fact that, in the new millennium a more aggressive
endovascular approach for AIOD was employed, based on
experience accumulated during the previous years; addi-
tionally, following Food and Drug Administration (FDA)
approval of endovascular repair of infrarenal abdominal
aortic aneurysms in 1999, the number of endovascular
procedures being performed by vascular surgeons was
expanded. Recorded information included patient demo-
graphics, presenting symptoms, risk factors and co-
morbidities, preoperative investigations, prior vascular
surgery, previous endoluminal intervention, operative
details (graft material used, end-to-end vs. end-to-side
proximal anastomosis, concomitant infrainguinal proce-
dure, femoral or aortic endarterectomy, concomitant renal
revascularisation, and inferior mesenteric artery reim-
plantation), postoperative morbidity and mortality, assis-
ted primary and secondary patency (defined as patency of
one or both limbs) and other long-term complications
(including pseudo-aneurysm, incisional hernia and graft
infection). Significant cardiac, pulmonary, renal, gastroin-
testinal, infectious, neurologic, bleeding and thrombotic
complications, limb loss and re-operations and other severe
complications were considered as morbidity. Patients were
followed-up for at least 6 months postoperatively. Report-
ing standards were used for outcome definitions.12 Approval
from the hospital institutional review board was obtained
prior to data collection.
Statistics
All data were analysed with Statistical Package for Social
Sciences (SPSS) 14.0 for Windows (SPSS Inc., Chicago, IL,
USA). The KolmogoroveSmirnov test was used to test
numerical data for normal distribution; normally distrib-
uted data were expressed as mean and standard deviation
and compared with the t-test; otherwise, they were
expressed as median and interquartile range (IQR,
25the75th percentile) and distribution-free tests methods
(ManneWhitney test or Wilcoxon signed-rank test, as
appropriate) were used. Categorical data were analysed
with the chi-square test (or Fisher’s exact test where
appropriate). Graft patency (confirmed by imaging) and
survival rates were calculated with the KaplaneMeier
method and compared with the log-rank (ManteleCox) test.
Multivariate analysis of the effect of clinical parameters on
these rates was performed with the Cox regression method
(forwards and backwards Wald models). A P value  0.05
was considered as significant.
Results
A comparison of patient characteristics, interventions
performed and postoperative complications during the two
study periods are shown in Tables 1e4. During 2000e07,
AFB was performed more frequently for patients with AIOD
presenting with tissue loss/rest pain than for other indica-
tions (48% vs. 31% before 2000, P Z 0.009) and also for
women (51% vs. 32% before 2000, PZ 0.003), (Table 1). An
increased prevalence of hypertension and hyperlipidaemia
was observed during the second study interval (Table 2),
Table 1 Baseline patient demographics and clinical presentation.
Study period P value All patients (n Z 269)
1993e2000 (n Z 187) 2001e2007 (n Z 82)
Age (median, IQR) 66 (57e72) 66 (58e70) .39 66 (58e72)
Gender (females, %) 60 (32%) 42 (51%) .003 102 (38%)
Race (African American, %) 54 (29%) 32 (39%) .12 86 (32%)
Indication
Intermittent claudication 62 (33%) 24 (29%) 86 (32%)
Critical limb ischaemia 58 (31%) 39 (48%) .009a 97 (36%)
Rest pain 41 (22%) 26 (32%) 67 (25%)
Tissue loss 17 (9%) 13 (16%) 30 (11%)
Aneurysmo-occlusive disease 67 (36%) 19 (23%) 86 (32%)
Significant P values appear in bold.
a Critical limb ischaemia vs. other indications.
660 S.K. Kakkos et al.while a reverse trend for chronic obstructive pulmonary
disease (COPD) and chronic kidney disease (serum
creatinine > 1.5 mg dl1, CKD) was observed. Patients from
both intervals had a similar incidence of prior interven-
tions, but a significantly increasing role for preoperative
cross-sectional imaging was noted during the most recent
study interval (Table 3). Operative techniques and the
frequency with which various adjuncts were employed
remained largely unchanged over the entire study period
(Table 4). In the vast majority of patients (244 or 91%),
polytetrafluoroethylene (PTFE) grafts were used; Dacron
grafts were used in the remaining 25 patients.
Thirty-day mortality was reduced during 2000e2007 to
2.4%, compared with 4.3% during 1993e1999, although this
difference was not statistically significant (PZ 0.73) (Table
5). Morbidity (43% vs. 44%, P Z 0.86) did not change
substantially over the study period. Mortality (in-hospital
and at 30 and 90 days) was not associated with operative
indication, patient demographics, risk factors or co-
morbidities (alone or in toto), prior intervention history
or surgical techniques used, with the exception of CKD; theTable 2 Baseline patient risk factors and co-morbidities.
Study period
1993e2000 (n Z 187) 200
Risk Factors
Smoking 143 (77%) 65
Hypertension 120 (64%) 63
Hyperlipidaemia 69 (37%) 52
Diabetes mellitus 38 (20%) 25
Co-morbitities
Coronary artery disease 83 (44%) 31
Chronic kidney disease 23 (12%) 4
COPD 40 (21%) 9
Prior stroke 20 (11%) 8
Malignancy 22 (12%) 4
Liver disease 5 (2.7%) 2
Other* 2 (1%) 4
COPD Z chronic obstructive pulmonary disease. *CHF (n Z 2), auto
(n Z 1).
Significant P values appear in bold.latter was associated with a higher in-hospital mortality
(11.1% vs. 2.1%, P Z 0.036, odds ratio (OR) 5.9, 95%
confidence interval (CI) Z 1.3e26.3) and a trend for
a higher 30-day (11.1% vs. 2.9%, PZ 0.07) mortality. Thirty-
day mortality in patients with CLI was 4.1% compared with
1.2% in patients presenting with claudication (PZ 0.37). On
multivariate analysis, predictors of in-hospital mortality
were CKD and co-morbidities listed as ‘other’ in Table 2
(hazard risk 11.6, 95% CI 1.1e123, P Z 0.013, and 7.3,
95% CI 1.5e34, P Z 0.042, respectively), CKD was the only
predictor of 30-day mortality (hazard risk 4.2, 95% CI
1.0e17, P Z 0.047) and age the only predictor of 90-day
mortality (hazard risk 1.07, 95% CI 1.004e1.14, PZ 0.037).
With regard to long-term outcome, the mean follow-up
period was 6.2 years (range 0e14.8 years); for survivors,
the mean follow-up period was 7.4 years (median 8 years),
while in the 1993e1999 group, mean and median follow-up
period rose to 10.8 years. The follow-up rate for the
1993e1999 group was 85.2% at 10 years. Although 23% of all
patients were lost from follow-up, their clinical data up to
their last visit were used and their survival status wasP value All patients (n Z 269)
1e2007 (n Z 82)
(79%) .61 208 (77%)
(77%) .04 183 (68%)
(63%) <.001 121 (45%)
(30%) .07 63 (23%)
(38%) .32 114 (42%)
(5%) .06 27 (10%)
(11%) .04 49 (18%)
(10%) 1.00 28 (10%)
(5%) .08 26 (10%)
(2.4%) 1.00 7 (2.6%)
(5%) .07 6 (2%)
immune disease (n Z 2), pulmonary embolism (n Z 1) and IVDA
Table 3 History of previous interventions and preoperative imaging studies performed during the two study periods.
Study period P value All patients (n Z 269)
1993e2000 (n Z 187) 2001e2007 (n Z 82)
History of prior intervention
Angioplasty/stenting 10 (5.3%) 5 (6.1%) .78 15 (5.6%)
Femoro-femoral bypass 2 (1.1%) 2 (2.4%) .59 4 (1.5%)
Aortic surgery 7 (3.7%) 2 (2.4%) .73 9 (3.3%)
Preoperative imaging .004
Angiography 172 (92%) 71 (87%) 243 (90%)
CTA/MRA 6 (3.2%) 11 (13%) 17 (6.3%)
Ultrasound 2 (1.1%) 0 (0%) 2 (.7%)
none 7 (3.7%) 0 (0%) 7 (2.6%)
Significant P values appear in bold.
CT Z Computerized tomography, CTA Z Computerized tomographic angiography, MRA Z Magnetic resonance angiography.
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data on patient survival are virtually complete. Anasto-
motic aneurysms occurred in only 1.1%, graft infection in
1.9% and incisional hernia in 3.7%. Dacron grafts were more
often associated with graft infection than were PTFE grafts
(12% vs. 0.8%, OR 16.5, 95% CI 2.6e104, P Z 0.006). Graft-
limb occlusion occurred in 5.6% of cases. Five- and 10-year
assisted primary patency was 95% and 88%, respectively
(Fig. 1). The corresponding results for secondary patency
were 99% and 95% (Fig. 1). Five-year assisted primary
patency (94% vs. 97%, P Z 0.15) and secondary patency
(98.6% vs. 100%, PZ 0.32) rates were similar during the two
study intervals (Fig. 2(a) and (b)). On multivariate analysis
(Cox regression), only younger age (defined as less than the
median e 66 years) was associated with worse patency
(P Z 0.01, relative risk 7, 95% CI 1.6e31).
Survival at 5 and 10 years was 69% and 48%, respectively,
with 136 patients (50.6%) expiring over the study course;
the five-year survival during the two study intervals was
67.9% and 68.3%, respectively, PZ 0.59 (Fig. 3). Significant
predictors of long-term mortality on log-rank test are
shown in Table 6. Older patient age (hazard risk 1.92, 95%
CI Z 1.49e2.48 for the second and third quartiles of age
(58e71 years) and 3.8, 95% CI Z 2.97e4.95, for the fourthTable 4 Operative details.
Study period
1993e2000 (n Z 187) 2
Proximal adjunctive procedure
Aortic endarterectomy 24 (13%)
Aortorenal endarterectomy 4 (2%)
Aortorenal bypass grafting 19 (10%)
Graft material
PTFEa 172 (92%) 7
Dacron 15 (8%) 1
End-to-side aortic anastomosis 10 (5.3%)




a PTFE Z polytetrafluoroethylene.quartile of age (older than 71 years), compared to the first
quartile of age (<58 years,) P < 0.001), CKD (hazard risk
1.95, 95% CIZ 1.22e3.12, PZ 0.005) and diabetes (hazard
risk 1.45, 95% CI Z 1.01e2.15, P Z 0.042) were the only
independent predictors of worse long-term survival.
Patients undergoing concomitant renal artery revascular-
isation (endarterectomy, n Z 8 or bypass, n Z 24, all
performed with no mortality) had similar long-term survival
compared with those who did not.Discussion
In this study, we documented a change in the indications
and gender of patients undergoing AFB over the past 15
years, with CLI and female gender being more common
during recent years. Despite these changes, perioperative
mortality and morbidity for AFB remained low. Mortality
actually improved during the second half of the study,
although this difference did not reach statistical signifi-
cance because of the small event number, and most likely
represents a type II error.
After 2000, more procedures were performed for CLI
rather than claudication. This observation might beP value All patients (n Z 269)
001e2007 (n Z 82)
5 (6%) .15 29 (11%)
4 (5%) 8 (3%)
5 (6%) 24 (9%)
2 (88%) .28 244 (91%)
0 (12%) 25 (9%)
8 (9.8%) .18 18 (6.7%)
7 (8.5%) .25 15 (5.6%)
3 (3.7%) 1.00 11 (4.1%)
Table 5 Postoperative mortality and morbidity.
Study period P value All patients (n Z 269)
1993e2000 (n Z 187) 2001e2007 (n Z 82)
Mortality
In-hospital 6 (3.2%) 2 (2.4%) 1.00 8 (3%)
30-day 8 (4.3%) 2 (2.4%) .73 10 (3.7%)
90-day 10 (5.3%) 4 (4.9%) 1.00 14 (5.2%)
Morbidity 80 (43%) 36 (44%) .86 116 (43%)
Wound complications 29 (16%) 16 (20%) .42 45 (17%)
Infectious complications 25 (13%) 11 (13%) 1.00 36 (13%)
662 S.K. Kakkos et al.interpreted as the result of patient selection, with claudi-
cants undergoing endovascular treatment more often in
recent years because of less severe AIOD. However, such
a change in indication pattern has not been reported in
other series of AFB grafting we reviewed,4,13e18 which
might indicate that this finding was the result of a local
policy change regarding indications for revascularisation.
This patient selection practice is reinforced by current
guidelines, which reserve open techniques for more
advanced anatomic patterns of atherosclerotic disease.8 As
a result, more patients with advanced vascular disease
were managed during the second part of the study. A
change in the referral pattern or a change in treatment
indications, including an increasing popularity of medical
management as a sole treatment modality, could also
explain this pattern change.
The percentage of females undergoing AFB grafting rose
over the course of the study period, a pattern noted in
other recent series (average 36% female),15e18 compared
with older ones (average 18% female).4,13,14,19 A similar
trend in the prevalence of myocardial infarction in midlife
females has recently been reported.20 Both these findings
could be the result of a relative deterioration in theFigure 1 Five- and 10-year assistedcardiovascular risk profile (including increased smoking) of
females compared with males in recent years.21 An alter-
native explanation is that women have an anatomic pattern
of disease less amenable to endoluminal intervention than
men and are therefore left with AFB as their only revas-
cularisation option. Our cohort of patients was older
compared with those in recent reports.4,13e19 The preva-
lence of hypertension and hyperlipidaemia increased over
the study period. This finding could be related to stricter
definitions of hyperlipidaemia22 and hypertension, or to
better recognition of these important risk factors by
primary care physicians. The prevalence of co-morbidities
did not change significantly over the course of the study.
An increasing complexity has been reported to occur in
peripheral vascular23 and abdominal aortic9,10 surgical
operations in recent years. This finding could be related to
previous revascularisation procedures (both open and
endovascular) and/or a change in patient selection for AFB
as a result of more widespread use of endovascular proce-
dures. However, no significant change in procedural
complexity, defined by a history of previous aortic inter-
vention or performance of a proximal adjunctive proce-
dure, inferior mesenteric artery reimplantation orprimary and secondary patency.
Figure 2 a. Assisted primary patency during the two study intervals. b. Secondary patency during the two study intervals.
AF2 Bypass Grafting in the Era of Endovascular Procedures 663a concomitant infrainguinal procedure was observed over
the course of this study (Tables 3 and 4).
Although a trend for decreasing morbidity over time has
been reported,1,4 this was not seen in our study; reportedrates vary between 20% and 32%,4,13,15e17 reflective of
inconsistent complication definition and/or reporting and
patient selection criteria. A similar trend for decreasing
mortality over time has also been reported,1,4 although
Figure 3 Patient survival at 5 and 10 years, similar during the two study intervals, is shown in this figure.
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studies performed over the two last decades3,4,13e19,24 with
no trend towards further reduction. Our mortality results
improved slightly over the course of the study (2.4% during
the second interval), perhaps due to the trend in per-
forming less complex aortic procedures in combination with
better patient selection and mostly improvement in pre-
and postoperative care, and are among the best reported,
despite the older age of our patients. This outcome may be
attributed to careful selection (standardised cardiac risk
assessment and routine postoperative care in a surgical
critical care unit). As CKD was associated with increased
mortality in our study, the decreased frequency of CKD
during the second interval of the study could also explain
the trend for reduced mortality. Likewise, COPD was less
prevalent during the second part of the study. Interestingly,
90-day mortality was higher, approximately 5%, and was
unchanged over the course of the study. Such a rise in
short-term mortality has been reported by others25 and
warrants further research to identify methods for
improvement.
Over the years, many studies have demonstrated the
durability of AFB grafting, reporting excellent long-term
patency and a very low rate of graft-related complica-
tions.2,4,26 In the current series, graft-related complica-
tions were equally rare, with similar rates being reported
during the two study intervals. Despite a change in
presentation pattern suggestive of more severe disease,
patency was similar during the two study intervals, with
overall excellent results (99% secondary patency rate at 5
years). This observation indicates that the durability of AFB
grafting was not influenced by changing indications and/or
patient population. Nevertheless, patency was worse insmokers, in agreement with clinical dictum and a previous
report.19 Also consistent with previous studies, incisional
hernia occurred more often when wound complications
arose.27e29 We did not document any advantage of PTFE
grafts over Dacron in terms of anastomotic aneurysm
formation, as previously shown, though the number of
Dacron grafts in this series was small.19
Survival at 5 and 10 years was 69% and 48%, respectively,
10e15% better than what it was four to six decades ago.4
Disappointingly, survival rates did not improve further
over the course of the study, though this is not totally
surprising, given the more advanced disease pattern with
which patients in the last interval presented. As expected,
diabetes and CKD were independent predictors of reduced
long-term survival. It remains to be seen if more aggressive
risk factor modification, the impact of which has been
realised only in recent years, will improve survival.22
Interestingly, concomitant renal artery revascularisation
did not confer any long-term survival advantage.30
Study limitations include its retrospective nature
(although patients were prospectively entered into a data-
base) and the absence of concurrent groups of patients
undergoing endovascular intervention,31 or medical inter-
vention alone for AIOD for comparison to this open surgery
population, to help explain our findings. Additionally,
patient follow-up was variable and perhaps not complete
regarding the development of infection, graft occlusion and
incisional hernias, the latter usually being evaluated and
managed by general surgeons, often in satellite hospitals.
In conclusion, in our experience, AFB is more likely to be
performed for tissue loss/rest pain and in women than in
the past. Despite these changes, perioperative mortality
and morbidity remain low. AFB continues to be a very
Table 6 Significant predictors of long-term mortality on univariate analysis (Log-rank test).
Predictor 10-year survival P value
Median age
<66 years (n Z 122) 64% <.001
66 years (n Z 147) 35%






















a CLI Z critical limb ischaemia.
b CKD Z chronic kidney disease.
AF2 Bypass Grafting in the Era of Endovascular Procedures 665durable procedure with excellent long-term patency and
low long-term complications and for now remains the gold-
standard intervention for AIOD.Conflict of Interest/Funding
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